期刊文献+

盐酸利多卡因跨膜肽纳米高分子脂质体的制备与体外透皮实验研究 被引量:3

Preparation of Lidocaine Hydrochloride-Loaded Transactivation Transcriptional Activator Conjugated Polymeric Liposomes and Its in Vitro Skin Permeation in Mice
下载PDF
导出
摘要 目的采用赖氨酸壳聚糖十八烷基季铵盐(OQLCS)组装跨膜肽(TAT)包载盐酸利多卡因制备纳米高分子脂质体,并研究其体外透皮渗透情况。方法采用反相蒸发法制备盐酸利多卡因跨膜肽纳米高分子脂质体(LID-TAT-PLs),使用离体小鼠皮和Franz扩散池进行体外透皮实验,HPLC法测定接收液中盐酸利多卡因的浓度,评价LID-TAT-PLs、未组装跨膜肽的盐酸利多卡因纳米高分子脂质体(LID-PLs)和盐酸利多卡因注射液(LID-IJ)的体外透皮渗透情况。结果 LID-TAT-PLs的体外透皮速度和累积透过量均明显高于LID-PLs和LID-IJ。LID-TAT-PLs组的24h累积透过量达(88.15±11.11)%,明显高于LID-PLs的(73.91±12.13)%和LID-IJ的(26.31±5.43)%,差异有统计学意义(P<0.05)。结论 TAT可以明显促进药物的透皮渗透,LID-TAT-PLs制备简单,具有良好的透皮释放行为。 Objective To prepare the lidocaine hydrochloride-loaded transactivation (TAT) conjugated octadecyl quaternized lysine modified chitosan polymeric liposomes (LID-TAT-PLs) and to study its in vitro skin permeation characters in mice. Methods LID-TAT-PLs were prepared by reverse-phase evaporation method. The concentrations of lidocaine hy- drochloride were determined by HPLC. The isolated mouse skin and Franz diffusion cell were used to evaluate the characters of permeation of LID-TAT-PLs, LID-PLs and lidocaine hydrochloride injection (LID-IJ). Results The permeation rate and cumulative permeation amount were significantly higher in LID-TAT-PLs group than those of LID-PLs and LID-IJ groups (P〈 0.05). Conclusion TAT can significantly enhance the transdermal permeation of drugs in mice. The LID-TAT-PLs can be prepared via a relatively simple method.
出处 《天津医药》 CAS 北大核心 2013年第3期227-229,共3页 Tianjin Medical Journal
基金 国家自然科学基金资助项目(项目编号:81070871) 天津市自然科学基金重点项目(项目编号:11JCZDJC20400)
关键词 利多卡因 赖氨酸壳聚糖十八烷基季铵盐 跨膜肽 纳米高分子脂质体 皮肤试验 透皮实验 lidoeaine octadeeyl quaternized lysine modified ehitosan transactivator polymetric liposomes skin tests permeation through skin
  • 相关文献

参考文献10

  • 1de Leeuw J, de Vijlder HC, Bjerring P, et al. Liposomes in dermatol- ogy today [J]. J Eur Acad Dermatol Venereol, 2009, 23 (5) : 505-516.
  • 2Torchilin VP. Tat peptide-mediated intracellular delivery of phar- maceutical nanocarriers [J]. Adv Drug Deliv Rev, 2008,60(4/5): 548-558.
  • 3Wang H, Zhao P, Liang X, et al. Construction of a novel cationic polymeric liposomes formed from PEGlated octadecyl-quaternized lysine modified chitosan/cholesterol for enhancing storage stability and cellular uptake efficiency [J]. Biotechnol Bioeng, 2010, 1066(6): 952-962.
  • 4李双艳,郝丽娟,韩磊,黄杰,常津.赖氨酸修饰壳聚糖磁性超微载体的制备和表征[J].高分子通报,2007(7):32-40. 被引量:7
  • 5赵明,李安民,常津,王汉杰,梁树立,张嘉靖,闫润民.改性壳聚糖包载的磁性紫杉醇纳米微粒的制备及对恶性脑胶质细胞瘤的抑制作用[J].生物医学工程学杂志,2011,28(3):513-516. 被引量:2
  • 6申明乐,王刚,李建成,万成堂,刘万锋,陈剑兵.司来吉兰贴片的制备及其体外透皮释放量的研究[J].中国新药杂志,2010,19(20):1907-1910. 被引量:5
  • 7Kang MJ, Eum JY, Jeong MS. Facilitated skin permeation of orego- nin by elastic liposomal formulations and suppression of atopic der- matitis in NC/Nga mice [J]. Biol Pharm Bull, 2010, 33(1):100-106.
  • 8Liu Y, Wang CY, Kong XH, et al. Novel multifunctional polyethyl- ene glycol-transactivating-transduction protein-modified lipo- somes cross the blood-spinal cord barrier after spinal cord injury [J]. J Drug Target, 2009,12(3):152-158.
  • 9He W, Guo X, Zhang M. Transdermal permeation enhancement of N-trimethyl chitosan for testosterone [J]. Int J Pharm, 2008,356(1/ 2):82-87.
  • 10Hasanovic A, Zehl M, Reznicek G, et al. Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability [J]. J Pharm Pharmaeol, 2009, 61(12): 1609-1616.

二级参考文献35

  • 1边佳明,赵维娟,许景峰.国外经皮给药系统的研究进展[J].中国药房,2005,16(14):1112-1114. 被引量:21
  • 2赵鹏,张本恕,肖颖,孔屏,孙峰.盐酸司来吉兰治疗早期帕金森病的疗效观察[J].临床神经病学杂志,2005,18(4):306-307. 被引量:9
  • 3Postma T J, Helmans J J, Luykx SA, et al. A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma [J]. Ann Oncol, 2000. 11(4) :409-413.
  • 4Marupudi N I, Han J E, Li K W, et al. Paelitaxel:a review of adverse toxicities and novel delivery strategies [J]. Expert Opin Drug Saf, 2007, 6(5) :609-621.
  • 5Glantz M J, Choy H, Kearns C M, et al. Paelitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors [J]. J Natl Cancer Inst, 1995, 19;87(14):1077- 1081.
  • 6Liang X F, Wang H J, Luo H, et al. Characterization of novel multifunctional cationic polymeric liposomes formed from octa- decyl quateruized carboxymethyl chitosao/cholesterol and drug encapsulation [J]. Langmuir, 2008, 24:7147-7153.
  • 7Wiegand S, Heinen T, Ramaswamy A, et al. Evaluation of the tolerance and distribution of intravenously applied ferrofluid particles of 250 and 500 nm size in an animal model [J]. J Drug Target, 2008, 17:1.
  • 8Mitra S, Gaur U, Ghosh P C, et al. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanopartieles as carrier [J]. J Control Release, 2001, 74 (1- 3) :317-323.
  • 9Liebmann J E, Cook J A, Lipschultz C, et al. Cytotoxic stud- ies of paclitaxel (Taxol) in human tumour cell lines [J]. Br J Cancer, 1993, 68(6) :1104-1109.
  • 10Legrand J,Taleb A,Gota S,Guittet M J,et al.Langmuir,2002,18:4131~4137.

共引文献9

同被引文献68

  • 1SHINGADE G M,AAMER Q,SABALE P M,et al. Review on:Recent trend on transdermal drug delivery system [ J ]. J Drug De-liv, 2012,2(1) :66-75.
  • 2PATIL P M,CHAUDHRI P D,PATEL J Ktet al. Recent trendsin challenges and opportunities of transdermal drug delivery sys-tem[ J], Int J Drug Dev Res,2012,4( 1 ) :39-50.
  • 3GOSWAMI D S. Permeation enhancer for TDDS from natural andsynthetic sources : A review [J] . J Biomed Pharm Res, 2013 , 2?1):19-29.
  • 4NASROLLAHI S A,TAGHIBIGLOU C,AZIZI E,et al Cell-pen-etrating peptides as a novel transdermal drug delivery system [ J ].Chem Biol Drug 2012,80(5) :639-646.
  • 5MAE M, LANGEL U. Cell-penetrating peptides as vectors for pep-tide, protein and oligonucleotide deli very [J]. Cun Opin Pharmacol,2006,6(5):509-514.
  • 6NAKASE I, TANAKA G,FUTAKI S. Cell-penetrating peptides(CPPs) as a vector for the delivery of siRNAs into cells[ J]. MolBiosyst ,2013 ,9(5) :S55~S61.
  • 7KAMEI N,MORISHITA M,EDA Y ,et al. Usefulness of cell-pen-etrating peptides to improve intestinal insulin absorption [ J] . JControlled Release,200^ ,132( 1 ) :21-25.
  • 8GREEN M,LOEWENSTEIN P M. Autonomous functional domains ofchemically synthesized human immunodeficiency virus tat trans-acti-vator protein[ J]. Cell,1988,55(6) : 1179-1188.
  • 9GREEN M ,ISHINO M, LOEWENSTEIN P M. Mutational analysisof HIY-1 Tat minimal domain peptides : Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression[J]. Cell,1989,58( 1):215-223.
  • 10BECHARA C, SAGAN S. Cell-penetrating peptides : Twenty yearslater, where do we stand [J]. FEBS Lett,2013,587(12) : 1693-1702.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部